Litfulo 50 MG Oral Capsule
- RxCUI
- 2641607
- RxNorm name
- Litfulo 50 MG Oral Capsule
- Display name
- Litfulo 50 MG Oral Capsule
- Full name
- Litfulo 50 MG Oral Capsule
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:02
UNII Substances#
No records found.
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Litfulo | RITLECITINIB | U.S. Pharmaceuticals | 1882f799-61b0-4813-965a-4910c4ae419c | 2026-06-17 | Boxed warning, Warnings, Adverse reactions | 2641607 |
| Litfulo | RITLECITINIB | Pfizer Laboratories Div Pfizer Inc | 6b2f9446-fb23-4741-b73a-5a2f993733c3 | 2026-06-17 | Boxed warning, Warnings, Adverse reactions | 2641607 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 6b2f9446-fb23-4741-b73a-5a2f993733c3 | Litfulo 50 MG Oral Capsule | PSN | 5 | These highlights do not include all the information needed to use LITFULO safely and effectively. See full prescribing information for LITFULO. LITFULO™ (ritlecitinib) capsules, for oral use Initial U.S. Approval: 2023 | 20260527 |
| 6b2f9446-fb23-4741-b73a-5a2f993733c3 | Litfulo 50 MG (equivalent to ritlecitinib tosylate 80.13 MG) Oral Capsule | SY | 5 | These highlights do not include all the information needed to use LITFULO safely and effectively. See full prescribing information for LITFULO. LITFULO™ (ritlecitinib) capsules, for oral use Initial U.S. Approval: 2023 | 20260527 |
| 6b2f9446-fb23-4741-b73a-5a2f993733c3 | ritlecitinib 50 MG Oral Capsule [Litfulo] | SBD | 5 | These highlights do not include all the information needed to use LITFULO safely and effectively. See full prescribing information for LITFULO. LITFULO™ (ritlecitinib) capsules, for oral use Initial U.S. Approval: 2023 | 20260527 |
| 1882f799-61b0-4813-965a-4910c4ae419c | Litfulo 50 MG (equivalent to ritlecitinib tosylate 80.13 MG) Oral Capsule | SY | 2 | These highlights do not include all the information needed to use LITFULO safely and effectively. See full prescribing information for LITFULO. LITFULO™ (ritlecitinib) capsules, for oral use Initial U.S. Approval: 2023 | 20250320 |
| 1882f799-61b0-4813-965a-4910c4ae419c | ritlecitinib 50 MG Oral Capsule [Litfulo] | SBD | 2 | These highlights do not include all the information needed to use LITFULO safely and effectively. See full prescribing information for LITFULO. LITFULO™ (ritlecitinib) capsules, for oral use Initial U.S. Approval: 2023 | 20250320 |
| 1882f799-61b0-4813-965a-4910c4ae419c | Litfulo 50 MG Oral Capsule | PSN | 2 | These highlights do not include all the information needed to use LITFULO safely and effectively. See full prescribing information for LITFULO. LITFULO™ (ritlecitinib) capsules, for oral use Initial U.S. Approval: 2023 | 20250320 |